BioNTech SE
22UA
株式のランク
#983
BioNTech SE is a biotechnology firm dedicated to the research, development, and... BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
株価
$96.49
時価総額
$24.24B
変化（1日）
1.69%
変化（1年）
-9.87%
国
DE
取引 BioNTech SE (22UA)
カテゴリー
Healthcare
BioNTech SE（22UA）の収益
Jun 2026 時点の収益 TTM: $3.14B
BioNTech SE の最新の財務報告によると、現在の収益 (TTM) は $3.14B です。2023 年には $4.22B の収益があり、これは 2022 年の $18.57B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
BioNTech SE の収益履歴（2017 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $3.14B | 9.54% |
| 2024 | $2.86B | -32.19% |
| 2023 | $4.22B | -77.26% |
| 2022 | $18.57B | -13.95% |
| 2021 | $21.58B | 3,573.62% |
| 2020 | $587.41M | 382.13% |
| 2019 | $121.84M | -16.89% |
| 2018 | $146.60M | 98.35% |
| 2017 | $73.91M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 302.58% |
US
|
|
| $2.23B | -28.95% |
US
|
|
| $15.74B | 402.07% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 92.01% |
NL
|
